Source: Virtual Congress 2020 – Experimental and laboratory studies in intensive care unit medicine
Disease area: Respiratory critical care



Rating:

Share or cite this content

Citations should be made in the following way:
Z. Donina (St. Petersburg, Russian Federation). Nonsteroid anti-inflammatory agents depress inflammation-related respiratory disoders and hypoxia-induced mortality. Experimental model.. 2758

Member's Comments

No comment yet.

Related content which might interest you: Neu-164, a novel antioxidant and anti-inflammatory compound reduces lung inflammation in a murine model of allergic asthma Source: Annual Congress 2008 - Comorbid cardiovascular condition and therapy of asthma Year: 2008 The anti-inflammatory effects of helminth-derived peptides in a model of endotoxin-induced acute lung injury Source: Virtual Congress 2021 – Environmental and lifestyle impacts on chronic lung disease Year: 2021 Ovalbumin-induced asthma model in Brown Norway rats demonstrates potential anti-asthmatic effects of Neu-164, a novel antioxidant and anti-inflammatory compound Source: Annual Congress 2008 - Understanding allergic airway inflammation with the help of animal models Year: 2008 Mechanisms of vascular endothelial cell injury in response to intermittent and continuous hypoxia exposure and protective effects of anti-inflammatory and anti-oxidant agents Source: International Congress 2019 – Novel methods, diagnostics and biomarkers in chronic lung diseases Year: 2019 Macrolide effects on the prevention of COPD exacerbations Source: Eur Respir J 2012; 40: 485-494 Year: 2012 An antedrug of the CXCL12 neutraligand blocks experimental allergic asthma without systemic effect in the mouse Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013 The anti-inflammatory effects of eucalyptol in a mouse model of LPS-induced pulmonary inflammation are mediated by TRPM8 Source: International Congress 2016 – Therapeutic horizons: novel targets and pharmacological models Year: 2016 The effects of intra-nasally administered anti-inflammatory compounds in a mouse model of acute COPD exacerbations Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013 The anti-inflammatory effects of PF03715455 and roflumilast on both cellular and tissue inflammation in a mouse model of COPD Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013 Late Breaking Abstract - The outcome of COVID-19 in interstitial lung disease patients treated with anti-inflammatory drugs and antiviral drugs Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021 Local and systemic imbalance of pro- and antiinflammatory cytokines in COPD Source: Annual Congress 2009 - Airway inflammation and host defence Year: 2009 Exploitation of anti-inflammatory mechanisms for the treatment of severe asthma Source: Annual Congress 2005 - Mechanisms of resolution of inflammation Year: 2005 Anti-inflammatory effect of hypoxic signaling suppression in the severe COPD model. Source: International Congress 2018 – COPD: novel pathological mechanisms in the airway epithelium Year: 2018 Neu-164, a novel antioxidant and anti-inflammatory compound, reduces cigarette smoke-induced lung inflammation Source: Annual Congress 2008 - COPD Year: 2008 Monitoring anti-inflammatory treatments in IPF and related disorders Source: Annual Congress 2004 - Pathobiological methodologies in monitoring immunomodulatory treatments Year: 2004 The mechanisms of antiinflammatory effect of mucolytic therapy Source: International Congress 2014 – Predictors Year: 2014 Mucolytics and anti-inflammatory lung treatments Source: ERS course 2015 Year: 2015 Differential effects of simvastatin and dexamethasone on TLR3-induced anti-viral cytokines in asthmatic epithelium Source: Annual Congress 2013 –Studies of asthma in man Year: 2013 Rosuvastatin effects on systemic inflammation, oxidative stress and antioxidants in patients with chronic obstructive pulmonary disease Source: International Congress 2016 – COPD diagnosis and management Year: 2016